- Vistagen Therapeutics Inc (NASDAQ:VTGN) completed an interim analysis of PALISADE-2, its second Phase 3 trial assessing drug candidate PH94B as an acute treatment of anxiety in adults with Social Anxiety Disorder.
- The analysis concluded that PALISADE-2 should continue as planned.
- Related: VistaGen Says Data From Late-Stage Anxiety Study ‘Not Consistent’ With Prior Positive Phase 2 Study.
- Independent biostatisticians reviewed unblinded data from the 140 subjects who completed PALISADE-2 before the Company paused enrollment in the study in July 2022, following the announcement of topline results from its first Phase 3 trial, PALISADE-1.
- The independent biostatisticians recommended that Vistagen continue PALISADE-2 as planned to the full enrollment of 208 subjects without adjusting the study size.
- Vistagen expects topline results from PALISADE-2 in the first half of 2023.
- Price Action: VTGN shares are up 21.8% at $0.20 on the last check Thursday.
Small-Cap ARCA Biopharma Stock Soars On Merger Pact: The Details
ARCA Biopharma and Oruka Therapeutics merge, focusing on novel biologics for chronic skin diseases like plaque psoriasis. ORKA-001 and ORKA-002 advance, supported by $275 million investment. Expect clinical trials in 2025. Merger closes Q3 2024. ABIO shares up 81.3% premarket."
